Report

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED & REGIONAL SCOPE 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.2 RESEARCH APPROACH 43
2.2.1 SECONDARY DATA 44
2.2.1.1 Key data from secondary sources 44
2.2.2 PRIMARY DATA 45
2.2.2.1 Primary sources 46
2.2.2.2 Key data from primary sources 46
2.2.2.3 Key industry insights 48
2.2.2.4 Breakdown of primary interviews 48
2.3 MARKET SIZE ESTIMATION 49
2.3.1 BOTTOM-UP APPROACH 49
2.3.1.1 Approach 1: Company revenue estimation approach 50
2.3.1.2 Approach 2: Presentations of companies and primary interviews 50
2.3.1.3 Growth forecasts 50
2.3.1.4 CAGR projections 51
2.3.2 TOP-DOWN APPROACH 51
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 52
2.5 MARKET SHARE 53
2.6 ASSUMPTIONS & LIMITATIONS 54
2.6.1 STUDY ASSUMPTIONS 54
2.6.2 GROWTH RATE ASSUMPTIONS 54
2.6.3 LIMITATIONS 55
2.7 RISK ASSESSMENT 55
2.7.1 RISK ASSESSMENT: HUMAN ORGANOIDS MARKET 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 63
4.1 HUMAN ORGANOIDS MARKET OVERVIEW 63
4.2 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029 63
4.3 HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029 64
4.4 HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029 64
4.5 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029 65
4.6 HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029 65
4.7 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66
5 MARKET OVERVIEW 67
5.1 INTRODUCTION 67
5.2 MARKET DYNAMICS 67
5.2.1 DRIVERS 68
5.2.1.1 Growing focus on developing alternatives to animal testing 68
5.2.1.2 Rising R&D funding and venture capital investments 69
5.2.1.3 Increasing research on organoids 70
5.2.1.4 Increasing prevalence of non-alcoholic fatty liver disease 70
5.2.1.5 Need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure 71
5.2.2 RESTRAINTS 72
5.2.2.1 Issues related to incorporating organoids into existing workflows 72
5.2.3 OPPORTUNITIES 72
5.2.3.1 Increasing focus on drug discovery activities 72
5.2.3.2 Rising demand for organ transplantation 74
5.2.3.3 Growth opportunities in emerging economies 75
5.2.4 CHALLENGES 75
5.2.4.1 Dearth of skilled professionals 75
5.3 PRICING ANALYSIS 76
5.3.1 AVERAGE SELLING PRICE, BY PRODUCT 76
5.3.2 AVERAGE SELLING PRICE, BY REGION 77
5.4 PATENT ANALYSIS 78
5.4.1 LIST OF MAJOR PATENTS 79
5.5 VALUE CHAIN ANALYSIS 80
5.6 SUPPLY CHAIN ANALYSIS 82
5.7 TRADE ANALYSIS 83
5.7.1 IMPORT DATA (HS CODE 3002) 83
5.7.2 EXPORT DATA (HS CODE 3002) 84
5.8 ECOSYSTEM ANALYSIS 84
5.8.1 ROLE IN ECOSYSTEM 85
5.9 PORTER'S FIVE FORCES ANALYSIS 86
5.9.1 THREAT OF NEW ENTRANTS 87
5.9.2 THREAT OF SUBSTITUTES 87
5.9.3 BARGAINING POWER OF BUYERS 87
5.9.4 BARGAINING POWER OF SUPPLIERS 88
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 88
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 88
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
5.10.2 KEY BUYING CRITERIA 89
5.11 REGULATORY LANDSCAPE 89
5.11.1 KEY REGULATIONS 90
5.11.1.1 North America 90
5.11.1.1.1 US 90
5.11.1.1.2 Canada 90
5.11.1.2 Europe 90
5.11.1.3 Asia Pacific 91
5.11.1.3.1 China 91
5.11.1.3.2 Japan 91
5.11.1.3.3 India 91
5.11.1.4 Latin America 91
5.11.1.4.1 Brazil 91
5.11.1.4.2 Mexico 92
5.11.1.5 Middle East & Africa 92
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
5.11.2.1 North America 92
5.11.2.2 Europe 93
5.11.2.3 Asia Pacific 93
5.11.2.4 Latin America 94
5.11.2.5 Rest of the world 94
5.12 TECHNOLOGY ANALYSIS 94
5.12.1 KEY TECHNOLOGIES 95
5.12.1.1 Stem Cell Technology 95
5.12.2 COMPLEMENTARY TECHNOLOGIES 95
5.12.2.1 3D Bioprinting 95
5.12.3 ADJACENT TECHNOLOGIES 95
5.12.3.1 Organ-on-a-Chip 95
5.13 KEY CONFERENCES AND EVENTS IN 2024-2025 96
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS 97
5.15 INVESTMENT AND FUNDING SCENARIO 97
5.16 CASE STUDY ANALYSIS 98
5.16.1 CASE STUDY 1: EVALUATION OF PATIENT-DERIVED ORGANOIDS FOR DRUG SENSITIVITY TESTING IN METASTATIC COLORECTAL CANCER WITH LIMITED TREATMENT OPTIONS 98
5.16.2 CASE STUDY 2: DEVELOPING STABLE ORGANOID MODELS FROM GASTRIC CANCER TISSUES FOR PERSONALIZED MEDICINE AND DRUG SCREENING 99
5.16.3 CASE STUDY 3: OPTIMAL CULTIVATION PERIODS FOR BLADDER CANCER ORGANOIDS BASED ON TRANSCRIPTOMIC PLASTICITY 99
5.17 IMPACT OF AI ON HUMAN ORGANOIDS MARKET 100
5.17.1 KEY USE CASES 101
6 HUMAN ORGANOIDS MARKET, BY PRODUCT 102
6.1 INTRODUCTION 103
6.2 LIVER MODELS 103
6.2.1 2D LIVER MODELS 107
6.2.1.1 Fresh hepatocytes 108
6.2.1.1.1 Increased drug metabolism studies to drive market 108
6.2.1.2 Cryopreserved hepatocytes 109
6.2.1.2.1 High quality and response to support market growth 109
6.2.1.3 Other 2D liver models 110
6.2.2 3D LIVER MODELS 111
6.2.2.1 Liver organoids 112
6.2.2.1.1 Support for determining pharmacology and hepatic toxicity of drugs to treat NAFLD 112
6.2.2.2 3D bioprinted liver models 113
6.2.2.2.1 Increased use in drug discovery to propel market growth 113
6.2.2.3 Liver spheroids 114
6.2.2.3.1 Need for better approaches in drug discovery to promote adoption of spheroids 114
6.2.2.4 Liver-on-a-chip 115
6.2.2.4.1 Stricter regulations on animal testing to promote adoption of in vitro systems like liver-on-a-chip 115
6.2.2.5 Other 3D liver models 116
6.3 KIDNEY MODELS 117
6.3.1 2D KIDNEY MODELS 120
6.3.1.1 Fresh kidney cells 121
6.3.1.1.1 Accurate representation and functionality to support usage 121
6.3.1.2 Cryopreserved kidney cells 122
6.3.1.2.1 Long-term storage benefits to drive market 122
6.3.1.3 Other 2D kidney models 123
6.3.2 3D KIDNEY MODELS 123
6.3.2.1 Kidney organoids 124
6.3.2.1.1 Increasing incidence of chronic kidney disease to boost market growth 124
6.3.2.2 3D bioprinted kidney models 125
6.3.2.2.1 High cost of bioprinting to hinder market growth 125
6.3.2.3 Kidney spheroids 126
6.3.2.3.1 Feasibility of studying challenging kidney diseases to drive adoption 126
6.3.2.4 Other 3D kidney models 126
6.4 PANCREATIC MODELS 127
6.4.1 2D PANCREATIC MODELS 130
6.4.1.1 Fresh pancreatic cells 131
6.4.1.1.1 High responsiveness to stimuli to support demand 131
6.4.1.2 Cryopreserved pancreatic cells 132
6.4.1.2.1 Potential use of cryopreserved cells in regenerative therapies and transplantation to increase demand 132
6.4.1.3 Other 2D pancreatic models 133
6.4.2 3D PANCREATIC MODELS 133
6.4.2.1 Pancreatic organoids 134
6.4.2.1.1 Increasing prevalence of diabetes and pancreatic cancer to drive uptake of pancreatic organoids 134
6.4.2.2 3D bioprinted pancreatic models 135
6.4.2.2.1 Precise fabrication and close resemblance to native architecture to drive adoption 135
6.4.2.3 Pancreatic spheroids 136
6.4.2.3.1 Improved methods for 3D cell culture to promote spheroid formation and support market growth 136
6.4.2.4 Other 3D pancreatic models 137
6.5 COLORECTAL MODELS 137
6.5.1 2D COLORECTAL MODELS 140
6.5.1.1 Fresh colorectal cells 141
6.5.1.1.1 Increasing incidence of colorectal cancer worldwide to heighten demand for fresh cells 141
6.5.1.2 Cryopreserved colorectal cells 142
6.5.1.2.1 Ability to thaw and culture cells on demand to support efficient research process, reducing need for continuous tissue sourcing 142
6.5.1.3 Other 2D colorectal models 143
6.5.2 3D COLORECTAL MODELS 144
6.5.2.1 Colorectal organoids 145
6.5.2.1.1 Drive to enhance therapeutic interventions will support growth 145
6.5.2.2 3D bioprinted colorectal models 146
6.5.2.2.1 Increasing bioburden of colorectal cancer to drive market growth 146
6.5.2.3 Colorectal spheroids 147
6.5.2.3.1 Advantages in determining disease mechanisms and drug testing to drive adoption 147
6.5.2.4 Other 3D colorectal models 147
6.6 HEART MODELS 148
6.6.1 2D HEART MODELS 151
6.6.1.1 Fresh heart cells 152
6.6.1.1.1 Importance in regenerative medicine applications to support adoption 152
6.6.1.2 Cryopreserved heart cells 152
6.6.1.2.1 On-demand access for clinical or research use to drive uptake of cryopreserved cells 152
6.6.1.3 Other 2D heart models 153
6.6.2 3D HEART MODELS 154
6.6.2.1 Heart organoids 155
6.6.2.1.1 Rising demand in cardiogenesis research to propel market growth 155
6.6.2.2 3D bioprinted heart models 155
6.6.2.2.1 High production costs to hinder adoption 155
6.6.2.3 Heart spheroids 156
6.6.2.3.1 Challenges in controlling spheroid morphology to restrain growth 156
6.6.2.4 Other 3D heart models 157
6.7 LUNG MODELS 158
6.7.1 2D LUNG MODELS 161
6.7.1.1 Fresh lung cells 162
6.7.1.1.1 Use of fresh lung cells gaining momentum due to their ability to accurately replicate native lung environment 162
6.7.1.2 Cryopreserved lung cells 163
6.7.1.2.1 Advancements in slicing and cryopreservation to enable creation of thousands of hPCLS from a single lung 163
6.7.1.3 Other 2D lung models 164
6.7.2 3D LUNG MODELS 164
6.7.2.1 Lung organoids 165
6.7.2.1.1 Increased adoption in biological research areas to boost market growth 165
6.7.2.2 3D bioprinted lung models 166
6.7.2.2.1 Advancements in bioinks to support uptake of 3D bioprinted lung models 166
6.7.2.3 Lung spheroids 167
6.7.2.3.1 Advantages of physiologically relevant environments for evaluating drug efficacy and toxicity to support usage 167
6.7.2.4 Other 3D lung models 168
6.8 OTHER PRODUCTS 168
6.8.1 2D MODELS (OTHER PRODUCTS) 171
6.8.1.1 Fresh cells (other products) 172
6.8.1.1.1 New techniques for isolating and preserving fresh cells to help enhance quality of research 172
6.8.1.2 Cryopreserved cells (other products) 173
6.8.1.2.1 Long-term storage benefits and advancements in research to support adoption 173
6.8.1.3 Other 2D models 174
?
6.8.2 3D MODELS (OTHER PRODUCTS) 175
6.8.2.1 Organoids (other products) 176
6.8.2.1.1 Growing focus on collaboration fosters innovation in organoid development 176
6.8.2.2 3D bioprinted models (other products) 177
6.8.2.2.1 Lack of suitable bioinks for 3D bioprinting applications to hamper market growth 177
6.8.2.3 Spheroids (other products) 178
6.8.2.3.1 Predictive environment for assessing efficacy and safety to support adoption 178
6.8.2.4 Other 3D models (other products) 179
7 HUMAN ORGANOIDS MARKET, BY SOURCE 180
7.1 INTRODUCTION 181
7.2 ADULT STEM CELLS 181
7.2.1 ADULT STEM CELLS TO HOLD LARGEST SHARE OF MARKET, BY SOURCE 181
7.3 INDUCED PLURIPOTENT STEM CELLS 184
7.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE UPTAKE OF IPSCS 184
7.4 EMBRYONIC STEM CELLS 186
7.4.1 ETHICAL CONCERNS ASSOCIATED WITH ESCS TO HINDER MARKET GROWTH 186
7.5 OTHER SOURCES 189
8 HUMAN ORGANOIDS MARKET, BY TYPE 192
8.1 INTRODUCTION 193
8.2 READY-TO-USE PRODUCTS 193
8.2.1 MASS PRODUCTION OF READY-TO-USE PRODUCTS TO DRIVE ADOPTION 193
8.3 CUSTOMIZABLE PRODUCTS 196
8.3.1 ADVANCEMENTS IN 3D BIOPRINTING TO PROPEL MARKET GROWTH 196
9 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD 200
9.1 INTRODUCTION 201
9.2 MATRIGEL MATRIX CULTURE 201
9.2.1 LONG-STANDING USE AND EFFECTIVENESS IN GROWING ORGANOIDS TO ENSURE ADOPTION 201
9.3 AIR-LIQUID INTERFACE CULTURE 204
9.3.1 INCREASING PREVALENCE OF DISEASES AFFECTING EPITHELIAL TISSUES TO DRIVE ADOPTION 204
9.4 SUSPENSION CULTURE 206
9.4.1 COST-EFFECTIVENESS OF SUSPENSION CULTURE TO DRIVE MARKET 206
9.5 3D BIOPRINTING CULTURE 209
9.5.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH 209
9.6 OTHER CULTURE METHODS 211
10 HUMAN ORGANOIDS MARKET, BY DISEASE AREA 214
10.1 INTRODUCTION 215
10.2 ONCOLOGY 215
10.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE IN ONCOLOGY TO DRIVE DEMAND FOR CANCER ORGANOIDS 215
10.3 LIVER DISEASES 218
10.3.1 INCREASING INCIDENCE OF LIVER-RELATED CONDITIONS TO DRIVE DEMAND FOR EFFECTIVE RESEARCH MODELS 218
10.4 GASTROINTESTINAL DISEASES 220
10.4.1 WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET 220
10.5 CARDIOVASCULAR DISEASES 223
10.5.1 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 223
10.6 INFECTIOUS DISEASES 225
10.6.1 USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH 225
10.7 NEUROLOGICAL DISORDERS 228
10.7.1 GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS 228
10.8 OTHER DISEASE AREAS 230
11 HUMAN ORGANOIDS MARKET, BY APPLICATION 233
11.1 INTRODUCTION 234
11.2 DEVELOPMENTAL BIOLOGY 234
11.2.1 TECHNOLOGICAL ADVANCEMENTS IN STEM CELL RESEARCH TO BOOST MARKET GROWTH 234
11.3 DRUG TOXICITY & EFFICACY TESTING 237
11.3.1 INCREASED DRUG DEVELOPMENT COSTS TO DRIVE GROWTH 237
11.4 DISEASE PATHOLOGY 239
11.4.1 INCREASED DEMAND FOR ADVANCED IN VITRO DISEASE STUDIES TO AUGMENT MARKET GROWTH 239
11.5 PERSONALIZED MEDICINE 242
11.5.1 HIGH COST AND INSUFFICIENT DATA TO HAMPER MARKET GROWTH 242
11.6 REGENERATIVE MEDICINE 244
11.6.1 INCREASING FUNDING ACTIVITIES TO PROPEL MARKET GROWTH 244
11.7 OTHER APPLICATIONS 247
12 HUMAN ORGANOIDS MARKET, BY END USER 250
12.1 INTRODUCTION 251
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 251
12.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET GROWTH 251
?
12.3 CONTRACT RESEARCH ORGANIZATIONS 254
12.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH 254
12.4 ACADEMIC & RESEARCH INSTITUTES 256
12.4.1 RISING GOVERNMENT FUNDING AND INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET 256
12.5 OTHER END USERS 259
13 HUMAN ORGANOIDS MARKET, BY REGION 262
13.1 INTRODUCTION 263
13.2 NORTH AMERICA 263
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 264
13.2.2 US 268
13.2.2.1 Rising prevalence of chronic respiratory diseases and organ transplants to expedite growth 268
13.2.3 CANADA 272
13.2.3.1 Growing incidence of cancer and investments in disease diagnostics & life science research to drive market 272
13.3 EUROPE 277
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 278
13.3.2 GERMANY 282
13.3.2.1 Higher healthcare spending and organ transplants to favor market growth 282
13.3.3 UK 286
13.3.3.1 Rising disease prevalence to drive market growth 286
13.3.4 FRANCE 290
13.3.4.1 Increasing availability of advanced medical technologies to support market growth 290
13.3.5 ITALY 294
13.3.5.1 Modernization of healthcare infrastructure to support market 294
13.3.6 SPAIN 297
13.3.6.1 Rising incidences of cancer to drive demand 297
13.3.7 REST OF EUROPE 301
13.4 ASIA PACIFIC 304
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 305
13.4.2 CHINA 310
13.4.2.1 Healthcare infrastructure improvements to support market growth in China 310
13.4.3 JAPAN 313
13.4.3.1 Rising biomedical & medical research to support market growth 313
13.4.4 INDIA 317
13.4.4.1 Large patient population and developing healthcare sector to drive market 317
?
13.4.5 AUSTRALIA 321
13.4.5.1 Rising private and public funding for research activities to drive market 321
13.4.6 SOUTH KOREA 325
13.4.6.1 Favorable government policies to fuel market growth 325
13.4.7 REST OF ASIA PACIFIC 329
13.5 LATIN AMERICA 332
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 334
13.5.2 BRAZIL 337
13.5.2.1 Growing pharmaceuticals market and budget allocations to boost market 337
13.5.3 MEXICO 341
13.5.3.1 Booming medical tourism to support growth 341
13.5.4 REST OF LATIN AMERICA 344
13.6 MIDDLE EAST & AFRICA 348
13.6.1 GROWING FOCUS ON IMPROVING QUALITY OF LIFE TO DRIVE MARKET 348
13.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 349
13.7 GCC COUNTRIES 352
13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO AUGMENT MARKET 352
13.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 353
14 COMPETITIVE LANDSCAPE 357
14.1 INTRODUCTION 357
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 357
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET 357
14.3 REVENUE ANALYSIS, 2021-2023 359
14.4 MARKET SHARE ANALYSIS, 2023 360
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 361
14.5.1 STARS 361
14.5.2 EMERGING LEADERS 362
14.5.3 PERVASIVE PLAYERS 362
14.5.4 PARTICIPANTS 362
14.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023 363
14.5.5.1 Company footprint 363
14.5.5.2 Region footprint 363
14.5.5.3 Product footprint 364
14.5.5.4 Source footprint 365
14.5.5.5 Application footprint 365
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 366
14.6.1 PROGRESSIVE COMPANIES 366
14.6.2 RESPONSIVE COMPANIES 366
14.6.3 DYNAMIC COMPANIES 366
14.6.4 STARTING BLOCKS 366
14.6.5 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023 367
14.7 COMPANY VALUATION AND FINANCIAL METRICS 368
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 369
14.8.1 BIOIVT 369
14.8.2 BECYTES BIOTECHNOLOGIES 369
14.9 COMPETITIVE SCENARIO 369
14.9.1 PRODUCT LAUNCHES 370
14.9.2 DEALS 370
15 COMPANY PROFILES 372
15.1 KEY PLAYERS 372
15.1.1 THERMO FISHER SCIENTIFIC INC. 372
15.1.1.1 Business overview 372
15.1.1.2 Products offered 373
15.1.1.3 Recent developments 374
15.1.1.3.1 Product launches 374
15.1.1.3.2 Deals 375
15.1.1.4 MnM view 375
15.1.1.4.1 Right to win 375
15.1.1.4.2 Strategic choices 375
15.1.1.4.3 Weaknesses and competitive threats 376
15.1.2 CORNING INCORPORATED 377
15.1.2.1 Business overview 377
15.1.2.2 Products offered 378
15.1.2.3 Recent developments 379
15.1.2.3.1 Deals 379
15.1.2.4 MnM view 379
15.1.2.4.1 Right to win 379
15.1.2.4.2 Strategic choices 380
15.1.2.4.3 Weaknesses and competitive threats 380
15.1.3 MERCK KGAA 381
15.1.3.1 Business overview 381
15.1.3.2 Products offered 382
15.1.3.3 Recent developments 383
15.1.3.3.1 Deals 383
15.1.3.3.2 Expansions 383
15.1.3.4 MnM view 383
15.1.3.4.1 Right to win 383
15.1.3.4.2 Strategic choices 383
15.1.3.4.3 Weaknesses and competitive threats 383
15.1.4 BIOIVT 384
15.1.4.1 Business overview 384
15.1.4.2 Products offered 384
15.1.4.3 Recent developments 388
15.1.4.3.1 Deals 388
15.1.4.4 MnM view 389
15.1.4.4.1 Right to win 389
15.1.4.4.2 Strategic choices 389
15.1.4.4.3 Weaknesses and competitive threats 389
15.1.5 HUB ORGANOIDS BV 390
15.1.5.1 Business overview 390
15.1.5.2 Products offered 390
15.1.5.3 Recent developments 390
15.1.5.3.1 Deals 390
15.1.5.4 MnM view 391
15.1.5.4.1 Right to win 391
15.1.5.4.2 Strategic choices 391
15.1.5.4.3 Weaknesses and competitive threats 391
15.1.6 BICO 392
15.1.6.1 Business overview 392
15.1.6.2 Products offered 393
15.1.6.3 Recent developments 394
15.1.6.3.1 Product launches 394
15.1.6.3.2 Deals 394
15.1.6.3.3 Other developments 394
15.1.7 BECYTES BIOTECHNOLOGIES 395
15.1.7.1 Business overview 395
15.1.7.2 Products offered 395
15.1.8 INSPHERO 396
15.1.8.1 Business overview 396
15.1.8.2 Products offered 396
15.1.8.3 Recent developments 397
15.1.8.3.1 Deals 397
15.1.9 GBA GROUP 398
15.1.9.1 Business overview 398
15.1.9.2 Products offered 398
15.1.9.3 Recent developments 398
15.1.9.3.1 Deals 398
15.1.10 KIRKSTALL LTD. 399
15.1.10.1 Business overview 399
15.1.10.2 Products offered 399
?
15.1.11 MIMETAS BV 400
15.1.11.1 Business overview 400
15.1.11.2 Products offered 400
15.1.11.3 Recent developments 401
15.1.11.3.1 Product launches 401
15.1.11.3.2 Deals 401
15.1.12 NEUROMICS 402
15.1.12.1 Business overview 402
15.1.12.2 Products offered 402
15.1.13 PRIMACYT CELL CULTURE TECHNOLOGY GMBH 404
15.1.13.1 Business overview 404
15.1.13.2 Products offered 404
15.1.14 STEMCELL TECHNOLOGIES 405
15.1.14.1 Business overview 405
15.1.14.2 Products offered 405
15.1.14.3 Recent developments 406
15.1.14.3.1 Expansions 406
15.2 OTHER PLAYERS 407
15.2.1 ACROBIOSYSTEMS 407
15.2.2 BIOPREDIC INTERNATIONAL 408
15.2.3 CN BIO INNOVATIONS LTD. 408
15.2.4 CYPRIO 409
15.2.5 EMULATE, INC. 410
15.2.6 KERAFAST, INC. 411
15.2.7 PANDORUM TECHNOLOGIES PVT. LTD. 411
15.2.8 CYFUSE BIOMEDICAL KK 412
15.2.9 NEYROBLASTGX LLC 413
15.2.10 3DNAMICS INC. 414
15.2.11 DEFINIGEN LIMITED 415
16 APPENDIX 416
16.1 DISCUSSION GUIDE 416
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 423
16.3 CUSTOMIZATION OPTIONS 425
16.4 RELATED REPORTS 425
16.5 AUTHOR DETAILS 426

TABLE 1 INVESTMENTS AND FUNDS FOR HUMAN ORGANOID RESEARCH 69
TABLE 2 RESEARCH PROJECTS AND ACTIVITIES 70
TABLE 3 AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY TYPE,
2022-2024 76
TABLE 4 AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY REGION,
2022-2024 77
TABLE 5 HUMAN ORGANOIDS MARKET: LIST OF MAJOR PATENTS, 2022-2023 79
TABLE 6 IMPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES,
WHETHER OR NOT MODIFIED, 2019-2023 (USD MILLION) 83
TABLE 7 EXPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES,
WHETHER OR NOT MODIFIED, BY COUNTRY, 2019-2023 (USD MILLION) 84
TABLE 8 HUMAN ORGANOIDS MARKET: ROLE IN ECOSYSTEM 85
TABLE 9 HUMAN ORGANOIDS MARKET: PORTER'S FIVE FORCES 87
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS (%) 89
TABLE 11 KEY BUYING CRITERIA FOR HUMAN ORGANOIDS, BY TYPE 89
TABLE 12 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 13 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 14 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 15 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 16 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 17 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY CONFERENCES
AND EVENTS, JANUARY 2024-DECEMBER 2025 96
TABLE 18 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 103
TABLE 19 LIVER MODELS: KEY PRODUCTS OFFERED, BY COMPANY 104
TABLE 20 LIVER AND INTRAHEPATIC BILE DUCT CANCER INCIDENCE, 2022 104
TABLE 21 HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY REGION,
2022-2029 (USD MILLION) 105
TABLE 22 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 23 EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 106
TABLE 24 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 106
TABLE 25 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 107
TABLE 26 HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY TYPE,
2022-2029 (USD MILLION) 107
TABLE 27 2D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 108
TABLE 28 2D LIVER MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 108
TABLE 29 FRESH HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY 109
TABLE 30 FRESH HEPATOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION) 109
TABLE 31 CRYOPRESERVED HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY 110
TABLE 32 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION,
2022-2029 (USD MILLION) 110
TABLE 33 OTHER 2D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 111
TABLE 34 3D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 112
TABLE 35 3D LIVER MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 112
TABLE 36 LIVER ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 113
TABLE 37 3D BIOPRINTED LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 114
TABLE 38 LIVER SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 115
TABLE 39 LIVER-ON-A CHIP MARKET, BY REGION, 2022-2029 (USD MILLION) 116
TABLE 40 OTHER 3D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 116
TABLE 41 KIDNEY MODELS: KEY PRODUCTS OFFERED, BY COMPANY 117
TABLE 42 KIDNEY CANCER INCIDENCE, 2022 117
TABLE 43 HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY REGION,
2022-2029 (USD MILLION) 118
TABLE 44 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 45 EUROPE: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 119
TABLE 46 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 119
TABLE 47 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 48 HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY TYPE,
2022-2029 (USD MILLION) 120
TABLE 49 2D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 121
TABLE 50 2D KIDNEY MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 121
TABLE 51 FRESH KIDNEY CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 122
TABLE 52 CRYOPRESERVED KIDNEY CELLS MARKET, BY REGION,
2022-2029 (USD MILLION) 122
TABLE 53 OTHER 2D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 123
TABLE 54 3D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 124
TABLE 55 3D KIDNEY MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 124
TABLE 56 KIDNEY ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 125
TABLE 57 3D BIOPRINTED KIDNEY MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 125
TABLE 58 KIDNEY SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 126
TABLE 59 OTHER 3D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 127
TABLE 60 PANCREATIC MODELS: KEY PRODUCTS OFFERED, BY COMPANY 127
TABLE 61 PANCREATIC CANCER INCIDENCE, 2022 128
TABLE 62 HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY REGION,
2022-2029 (USD MILLION) 128
TABLE 63 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 64 EUROPE: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 65 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 66 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 67 HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY TYPE,
2022-2029 (USD MILLION) 130
TABLE 68 2D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 131
TABLE 69 2D PANCREATIC MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 131
TABLE 70 FRESH PANCREATIC CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 132
TABLE 71 CRYOPRESERVED PANCREATIC CELLS MARKET, BY REGION,
2022-2029 (USD MILLION) 132
TABLE 72 OTHER 2D PANCREATIC MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 133
TABLE 73 3D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 134
TABLE 74 3D PANCREATIC MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 134
TABLE 75 PANCREATIC ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 135
TABLE 76 3D BIOPRINTED PANCREATIC MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 136
TABLE 77 PANCREATIC SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 136
TABLE 78 OTHER 3D PANCREATIC MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 137
TABLE 79 COLORECTAL MODELS: KEY PRODUCTS OFFERED, BY COMPANY 138
TABLE 80 COLORECTAL CANCER INCIDENCE, 2022 138
TABLE 81 HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY REGION,
2022-2029 (USD MILLION) 138
TABLE 82 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 83 EUROPE: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 84 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 85 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 140
TABLE 86 HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY TYPE,
2022-2029 (USD MILLION) 140
TABLE 87 2D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 141
TABLE 88 2D COLORECTAL MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 141
TABLE 89 FRESH COLORECTAL CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 142
TABLE 90 CRYOPRESERVED COLORECTAL CELLS MARKET, BY REGION,
2022-2029 (USD MILLION) 143
TABLE 91 OTHER 2D COLORECTAL MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 143
TABLE 92 3D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 144
TABLE 93 3D COLORECTAL MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 144
TABLE 94 COLORECTAL ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 145
TABLE 95 3D BIOPRINTED COLORECTAL MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 146
TABLE 96 COLORECTAL SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 147
TABLE 97 OTHER 3D COLORECTAL MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 148
TABLE 98 HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY REGION,
2022-2029 (USD MILLION) 149
TABLE 99 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS,
BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 100 EUROPE: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 149
TABLE 101 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 102 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 103 HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY TYPE,
2022-2029 (USD MILLION) 150
TABLE 104 2D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 151
TABLE 105 2D HEART MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 151
TABLE 106 FRESH HEART CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 152
TABLE 107 CRYOPRESERVED HEART CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 153
TABLE 108 OTHER 2D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 153
TABLE 109 3D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 154
TABLE 110 3D HEART MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 154
TABLE 111 HEART ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 155
TABLE 112 3D BIOPRINTED HEART MODELS MARKET, BY REGION,
2022-2029 (USD MILLION) 156
TABLE 113 HEART SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 157
TABLE 114 OTHER 3D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 157
TABLE 115 LUNG MODELS: KEY PRODUCTS OFFERED, BY COMPANY 158
TABLE 116 LUNG CANCER INCIDENCE,2022 158
TABLE 117 HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY REGION,
2022-2029 (USD MILLION) 159
TABLE 118 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 119 EUROPE: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 160
TABLE 120 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 121 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 122 HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY TYPE,
2022-2029 (USD MILLION) 161
TABLE 123 2D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 162
TABLE 124 2D LUNG MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 162
TABLE 125 FRESH LUNG CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 163
TABLE 126 CRYOPRESERVED LUNG CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 163
TABLE 127 OTHER 2D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 164
TABLE 128 3D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 165
TABLE 129 3D LUNG MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION) 165
TABLE 130 LUNG ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 166
TABLE 131 3D BIOPRINTED LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 167
TABLE 132 LUNG SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 167
TABLE 133 OTHER 3D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION) 168
TABLE 134 OTHER PRODUCTS: KEY PRODUCTS OFFERED, BY COMPANY 169
TABLE 135 BRAIN, CENTRAL NERVOUS SYSTEM, AND BREAST CANCER INCIDENCE, 2022 169
TABLE 136 OTHER HUMAN ORGANOID PRODUCTS MARKET, BY REGION,
2022-2029 (USD MILLION) 169
TABLE 137 NORTH AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 138 EUROPE: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 170
TABLE 139 ASIA PACIFIC: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 140 LATIN AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 141 OTHER HUMAN ORGANOID PRODUCTS MARKET, BY TYPE,
2022-2029 (USD MILLION) 171
TABLE 142 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 172
TABLE 143 2D MODELS (OTHER PRODUCTS) MARKET, BY TYPE,
2022-2029 (USD MILLION) 172
TABLE 144 FRESH CELLS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 173
TABLE 145 CRYOPRESERVED CELLS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 174
TABLE 146 OTHER 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 174
TABLE 147 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 175
TABLE 148 3D MODELS (OTHER PRODUCTS) MARKET, BY TYPE, 2022-2029 (USD MILLION) 176
TABLE 149 ORGANOIDS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 176
TABLE 150 3D BIOPRINTED MODELS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 177
TABLE 151 SPHEROIDS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION) 178
TABLE 152 OTHER 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION,
2022-2029 (USD MILLION) 179
TABLE 153 HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 181
TABLE 154 ADULT STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 182
TABLE 155 NORTH AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 182
TABLE 156 EUROPE: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 157 ASIA PACIFIC: ADULT STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 183
TABLE 158 LATIN AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 183
TABLE 159 INDUCED PLURIPOTENT STEM CELLS: KEY PRODUCTS OFFERED, BY COMPANY 184
TABLE 160 INDUCED PLURIPOTENT STEM CELLS MARKET, BY REGION,
2022-2029 (USD MILLION) 185
TABLE 161 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 162 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 185
TABLE 163 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 186
TABLE 164 LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 186
TABLE 165 EMBRYONIC STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION) 187
TABLE 166 NORTH AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 187
TABLE 167 EUROPE: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 188
TABLE 168 ASIA PACIFIC: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 188
TABLE 169 LATIN AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 189
TABLE 170 OTHER SOURCES: KEY PRODUCTS OFFERED, BY COMPANY 189
TABLE 171 OTHER HUMAN ORGANOID SOURCES MARKET, BY REGION,
2022-2029 (USD MILLION) 190
TABLE 172 NORTH AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 173 EUROPE: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 190
TABLE 174 ASIA PACIFIC: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 191
TABLE 175 LATIN AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 176 HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 193
TABLE 177 READY-TO-USE PRODUCTS MARKET: KEY PRODUCTS, BY COMPANY 194
TABLE 178 READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY REGION,
2022-2029 (USD MILLION) 194
TABLE 179 NORTH AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 180 EUROPE: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 195
TABLE 181 ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 195
TABLE 182 LATIN AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 183 CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY REGION,
2022-2029 (USD MILLION) 197
TABLE 184 NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 185 EUROPE: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 198
TABLE 186 ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 198
TABLE 187 LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 188 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION) 201
TABLE 189 HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY REGION, 2022-2029 (USD MILLION) 202
TABLE 190 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 202
TABLE 191 EUROPE: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 203
TABLE 192 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 203
TABLE 193 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 194 HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY REGION, 2022-2029 (USD MILLION) 205
TABLE 195 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 196 EUROPE: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 197 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 206
TABLE 198 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 206
TABLE 199 HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY REGION,
2022-2029 (USD MILLION) 207
TABLE 200 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 201 EUROPE: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 202 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 203 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 209
TABLE 204 HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY REGION,
2022-2029 (USD MILLION) 210
TABLE 205 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION) 210
TABLE 206 EUROPE: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 210
TABLE 207 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 211
TABLE 208 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE,
BY COUNTRY, 2022-2029 (USD MILLION) 211
TABLE 209 HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY REGION, 2022-2029 (USD MILLION) 212
TABLE 210 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 211 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS,
BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 212 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS,
BY COUNTRY, 2022-2029 (USD MILLION) 213
TABLE 213 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION) 213
TABLE 214 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION) 215
TABLE 215 INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE 216
TABLE 216 HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY REGION,
2022-2029 (USD MILLION) 216
TABLE 217 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 217
TABLE 218 EUROPE: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY,
2022-2029 (USD MILLION) 217
TABLE 219 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY,
2022-2029 (USD MILLION) 217
TABLE 220 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 218
TABLE 221 HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY REGION,
2022-2029 (USD MILLION) 219
TABLE 222 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 219
TABLE 223 EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 219
TABLE 224 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 220
TABLE 225 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 220
TABLE 226 HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022-2029 (USD MILLION) 221
TABLE 227 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 221
TABLE 228 EUROPE: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 222
TABLE 229 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 222
TABLE 230 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 223
TABLE 231 HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION) 224
TABLE 232 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 224
TABLE 233 EUROPE: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 224
TABLE 234 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 225
TABLE 235 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 225
TABLE 236 HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES BY REGION,
2022-2029 (USD MILLION) 226
TABLE 237 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 227
TABLE 238 EUROPE: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 227
TABLE 239 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 227
TABLE 240 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 228
TABLE 241 HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION) 229
TABLE 242 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 229
TABLE 243 EUROPE: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2022-2029 (USD MILLION) 229
TABLE 244 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2022-2029 (USD MILLION) 230
TABLE 245 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 230
TABLE 246 HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY REGION,
2022-2029 (USD MILLION) 231
TABLE 247 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS,
BY COUNTRY, 2022-2029 (USD MILLION) 231
TABLE 248 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 231
TABLE 249 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS,
BY COUNTRY, 2022-2029 (USD MILLION) 232
TABLE 250 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS,
BY COUNTRY, 2022-2029 (USD MILLION) 232
TABLE 251 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 234
TABLE 252 HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,
2022-2029 (USD MILLION) 235
TABLE 253 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 235
TABLE 254 EUROPE: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 236
TABLE 255 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 236
TABLE 256 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 237
TABLE 257 HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY REGION, 2022-2029 (USD MILLION) 238
TABLE 258 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 238
TABLE 259 EUROPE: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 238
TABLE 260 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY &
EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 239
TABLE 261 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY &
EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION) 239
TABLE 262 HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY REGION,
2022-2029 (USD MILLION) 240
TABLE 263 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 240
TABLE 264 EUROPE: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 241
TABLE 265 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 241
TABLE 266 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 242
TABLE 267 HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY REGION,
2022-2029 (USD MILLION) 243
TABLE 268 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION) 243
TABLE 269 EUROPE: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2022-2029 (USD MILLION) 243
TABLE 270 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2022-2029 (USD MILLION) 244
TABLE 271 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2022-2029 (USD MILLION) 244
TABLE 272 HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY REGION,
2022-2029 (USD MILLION) 245
TABLE 273 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION) 245
TABLE 274 EUROPE: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE,
BY COUNTRY, 2022-2029 (USD MILLION) 246
TABLE 275 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE,
BY COUNTRY, 2022-2029 (USD MILLION) 246
TABLE 276 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE,
BY COUNTRY, 2022-2029 (USD MILLION) 247
TABLE 277 HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY REGION,
2022-2029 (USD MILLION) 247
TABLE 278 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 248
TABLE 279 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 248
TABLE 280 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 248
TABLE 281 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 249
TABLE 282 HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 251
TABLE 283 HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION) 252
TABLE 284 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 252
TABLE 285 EUROPE: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL &
BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 253
TABLE 286 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 253
TABLE 287 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 254
TABLE 288 HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2022-2029 (USD MILLION) 255
TABLE 289 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 255
TABLE 290 EUROPE: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 255
TABLE 291 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 256
TABLE 292 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 256
TABLE 293 HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2022-2029 (USD MILLION) 257
TABLE 294 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC &
RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 258
TABLE 295 EUROPE: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 258
TABLE 296 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 258
TABLE 297 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 259
TABLE 298 HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY REGION,
2022-2029 (USD MILLION) 260
TABLE 299 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 260
TABLE 300 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 260
TABLE 301 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 261
TABLE 302 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 261
TABLE 303 HUMAN ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION) 263
TABLE 304 NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES
FROM 0 TO 85+ YEARS OF AGE, 2022-2045 265
TABLE 305 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 266
TABLE 306 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 266
TABLE 307 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 266
TABLE 308 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 267
TABLE 309 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 267
TABLE 310 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 267
TABLE 311 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 268
TABLE 312 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 268

TABLE 313 US: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 270
TABLE 314 US: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 270
TABLE 315 US: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 270
TABLE 316 US: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 317 US: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION) 271
TABLE 318 US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION) 271
TABLE 319 US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 272
TABLE 320 US: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 272
TABLE 321 ESTIMATED PREVALENCE OF DIABETES IN CANADA, 2022 VS. 2023 273
TABLE 322 CANADA: FIVE MOST-REPORTED CAUSES OF CANCER-RELATED MORTALITY, 2024 274
TABLE 323 CANADA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 274
TABLE 324 CANADA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 275
TABLE 325 CANADA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 275
TABLE 326 CANADA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 275
TABLE 327 CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 276
TABLE 328 CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 276
TABLE 329 CANADA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 277
TABLE 330 EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES
FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+] 278
TABLE 331 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 279
TABLE 332 EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 279
TABLE 333 EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 280
TABLE 334 EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 335 EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 280
TABLE 336 EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 281
TABLE 337 EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 281
TABLE 338 EUROPE: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 282
TABLE 339 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 283
TABLE 340 GERMANY: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 283
TABLE 341 GERMANY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 284
TABLE 342 GERMANY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 343 GERMANY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 284
TABLE 344 GERMANY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 285
TABLE 345 GERMANY: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 285
TABLE 346 GERMANY: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 286
TABLE 347 UK: INCIDENCE AND MORTALITY RATE OF HEART AND CIRCULATORY
DISEASES (CVD), 2024 286
TABLE 348 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 287
TABLE 349 UK: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 288
TABLE 350 UK: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 288
TABLE 351 UK: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 288
TABLE 352 UK: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 289
TABLE 353 UK: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION) 289
TABLE 354 UK: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 290
TABLE 355 UK: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 290
TABLE 356 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 291
TABLE 357 FRANCE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 291
TABLE 358 FRANCE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 292
TABLE 359 FRANCE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 360 FRANCE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 292
TABLE 361 FRANCE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 293
TABLE 362 FRANCE: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 293
TABLE 363 FRANCE: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 294
TABLE 364 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 295
TABLE 365 ITALY: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 295
TABLE 366 ITALY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 295
TABLE 367 ITALY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 296
TABLE 368 ITALY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 296
TABLE 369 ITALY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 296
TABLE 370 ITALY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 297
TABLE 371 ITALY: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 297
TABLE 372 SPAIN: CANCER INCIDENCE, 2022 VS 2023 298
TABLE 373 SPAIN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 298
TABLE 374 SPAIN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 299
TABLE 375 SPAIN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 299
TABLE 376 SPAIN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 299
TABLE 377 SPAIN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 300
TABLE 378 SPAIN: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 300
TABLE 379 SPAIN: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 301
TABLE 380 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 302
TABLE 381 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 302
TABLE 382 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 302
TABLE 383 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 303
TABLE 384 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 303
TABLE 385 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 304
TABLE 386 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 304
TABLE 387 ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES
FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+] 305
TABLE 388 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 307
TABLE 389 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 307
TABLE 390 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 308
TABLE 391 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 308
TABLE 392 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 308
TABLE 393 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 309
TABLE 394 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 309
TABLE 395 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 310
TABLE 396 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 311
TABLE 397 CHINA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 311
TABLE 398 CHINA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 311
TABLE 399 CHINA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 312
TABLE 400 CHINA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 312
TABLE 401 CHINA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 312
TABLE 402 CHINA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 313
TABLE 403 CHINA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 313
TABLE 404 JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 314
TABLE 405 JAPAN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 315
TABLE 406 JAPAN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 315
TABLE 407 JAPAN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 315
TABLE 408 JAPAN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 316
TABLE 409 JAPAN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 316
TABLE 410 JAPAN: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 317
TABLE 411 JAPAN: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 317
TABLE 412 INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 318
TABLE 413 INDIA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 319
TABLE 414 INDIA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 319
TABLE 415 INDIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 319
TABLE 416 INDIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 320
TABLE 417 INDIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 320
TABLE 418 INDIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 321
TABLE 419 INDIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 321
TABLE 420 AUSTRALIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 322
TABLE 421 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 323
TABLE 422 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 323
TABLE 423 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 323
TABLE 424 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 324
TABLE 425 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 324
TABLE 426 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 325
TABLE 427 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 325
TABLE 428 SOUTH KOREA: CANCER INCIDENCE, MORTALITY AND PREVALENCE,
BY TYPE, 2022 326
TABLE 429 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 326
TABLE 430 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 327
TABLE 431 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 327
TABLE 432 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 327
TABLE 433 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 328
TABLE 434 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 328
TABLE 435 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 329
TABLE 436 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 330
TABLE 437 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 330
TABLE 438 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 330
TABLE 439 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION) 331
TABLE 440 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 331
TABLE 441 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 332
TABLE 442 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 332
TABLE 443 LATIN AMERICA: ESTIMATED NUMBER OF CANCER NEW CASES
FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+] 333
TABLE 444 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 334
TABLE 445 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 334
TABLE 446 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 335
TABLE 447 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 335
TABLE 448 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 335
TABLE 449 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 336
TABLE 450 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 336
TABLE 451 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 337
TABLE 452 BRAZIL: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 338
TABLE 453 BRAZIL: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 338
TABLE 454 BRAZIL: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 339
TABLE 455 BRAZIL: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 339
TABLE 456 BRAZIL: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 339
TABLE 457 BRAZIL: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 340
TABLE 458 BRAZIL: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 340
TABLE 459 BRAZIL: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 341
TABLE 460 MEXICO: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022 342
TABLE 461 MEXICO: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 342
TABLE 462 MEXICO: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION) 342
TABLE 463 MEXICO: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 464 MEXICO: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 343
TABLE 465 MEXICO: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 343
TABLE 466 MEXICO: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 344
TABLE 467 MEXICO: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION) 344
TABLE 468 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 345
TABLE 469 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 345
TABLE 470 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 346
TABLE 471 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION) 346
TABLE 472 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 347
TABLE 473 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 347
TABLE 474 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 348
TABLE 475 AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES
BETWEEN 0 TO 85+ OF AGE, 2022-2045 349
TABLE 476 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 349
TABLE 477 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 350
TABLE 478 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 350
TABLE 479 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION) 350
TABLE 480 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 351
TABLE 481 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 351
TABLE 482 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 352
TABLE 483 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 353
TABLE 484 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY SOURCE,
2022-2029 (USD MILLION) 354
TABLE 485 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY TYPE,
2022-2029 (USD MILLION) 354
TABLE 486 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD,
2022-2029 (USD MILLION) 354
TABLE 487 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,
2022-2029 (USD MILLION) 355
TABLE 488 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 355
TABLE 489 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY END USER,
2022-2029 (USD MILLION) 356
TABLE 490 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN
HUMAN ORGANOIDS MARKET 357
TABLE 491 HUMAN ORGANOIDS MARKET: DEGREE OF COMPETITION 360
TABLE 492 HUMAN ORGANOIDS MARKET: REGION FOOTPRINT 363
TABLE 493 HUMAN ORGANOIDS MARKET: PRODUCT FOOTPRINT 364
TABLE 494 HUMAN ORGANOIDS MARKET: SOURCE FOOTPRINT 365
TABLE 495 HUMAN ORGANOIDS MARKET: APPLICATION FOOTPRINT 365
TABLE 496 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 367
TABLE 497 HUMAN ORGANOIDS MARKET: COMPETITIVE BENCHMARKING OF
STARTUP/SME PLAYERS 368
TABLE 498 HUMAN ORGANOIDS MARKET: PRODUCT LAUNCHES,
JANUARY 2021- AUGUST 2024 370
TABLE 499 HUMAN ORGANOIDS MARKET: DEALS, JANUARY 2021-AUGUST 2024 370
TABLE 500 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 372
TABLE 501 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 373
TABLE 502 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES,
JANUARY 2021-AUGUST 2024 374
TABLE 503 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021-AUGUST 2024 375
TABLE 504 CORNING INCORPORATED: COMPANY OVERVIEW 377
TABLE 505 CORNING INCORPORATED: PRODUCTS OFFERED 378
TABLE 506 CORNING INCORPORATED: DEALS, JANUARY 2021-AUGUST 2024 379
TABLE 507 MERCK: COMPANY OVERVIEW 381
TABLE 508 MERCK: PRODUCTS OFFERED 382
TABLE 509 MERCK: DEALS, JANUARY 2021-AUGUST 2024 383
TABLE 510 MERCK: EXPANSIONS, JANUARY 2021-AUGUST 2024 383
TABLE 511 BIOIVT: COMPANY OVERVIEW 384
TABLE 512 BIOIVT: PRODUCTS OFFERED 384
TABLE 513 BIOIVT: DEALS, JANUARY 2021-AUGUST 2024 388
TABLE 514 HUB ORGANOIDS: COMPANY OVERVIEW 390
TABLE 515 HUB ORGANOIDS: PRODUCTS OFFERED 390
TABLE 516 HUB ORGANOIDS: DEALS, JANUARY 2021-AUGUST 2024 390
TABLE 517 BICO: COMPANY OVERVIEW 392
TABLE 518 BICO: PRODUCTS OFFERED 393
TABLE 519 BICO: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024 394
TABLE 520 BICO: DEALS, JANUARY 2021-JUNE 2024 394
TABLE 521 BICO: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024 394
TABLE 522 BECYTES BIOTECHNOLOGIES: COMPANY OVERVIEW 395
TABLE 523 BECYTES BIOTECHNOLOGIES: PRODUCTS OFFERED 395
TABLE 524 INSPHERO: COMPANY OVERVIEW 396
TABLE 525 INSPHERO: PRODUCTS OFFERED 396
TABLE 526 INSPHERO: DEALS, JANUARY 2021-AUGUST 2024 397
TABLE 527 GBA GROUP: COMPANY OVERVIEW 398
TABLE 528 GBA GROUP: PRODUCTS OFFERED 398
TABLE 529 GBA GROUP: DEALS, JANUARY 2021-AUGUST 2024 398
TABLE 530 KIRKSTALL: COMPANY OVERVIEW 399
TABLE 531 KIRKSTALL: PRODUCTS OFFERED 399
TABLE 532 MIMETAS: COMPANY OVERVIEW 400
TABLE 533 MIMETAS: PRODUCTS OFFERED 400
TABLE 534 MIMETAS: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024 401
TABLE 535 MIMETAS: DEALS, JANUARY 2021-AUGUST 2024 401
TABLE 536 NEUROMICS: COMPANY OVERVIEW 402
TABLE 537 NEUROMICS: PRODUCTS OFFERED 402
TABLE 538 PRIMACYT CELL CULTURE TECHNOLOGY GMBH: COMPANY OVERVIEW 404
TABLE 539 PRIMACYT CELL CULTURE TECHNOLOGY GMBH: PRODUCTS OFFERED 404
TABLE 540 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 405
TABLE 541 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED 405
TABLE 542 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021-AUGUST 2024 406
TABLE 543 STEMCELL TECHNOLOGIES: EXPANSIONS, JANUARY 2021-AUGUST 2024 406